华夏稳增混合（519029）成立日期2006年8月9日，最新规模13.01亿。今年以来收益22.33%，同类排名 284/8891；近一年收益59.99%，同类排名784/8137；成立以来收益689.64%。 2月27日，麦澜德涨5.05%，截至发稿，报46.37元/股，成交7806.20万元，换手率1.73%，总市值46.37亿 元。 资料显示，南京麦澜德医疗科技股份有限公司位于江苏省南京市雨花台区凤展路32号A2栋，成立日期 2013年1月16日，上市日期2022年8月11日，公司主营业务涉及从事盆底及产后康复领域相关产品的研 发、生产、销售和服务。主营业务收入构成为：盆底康复产品36.98%，生殖康复产品33.10%，耗材及 配件24.32%，运动康复产品2.77%，其他(补充)2.18%，其他产品0.66%。 从麦澜德十大流通股东角度 数据显示，华夏基金旗下1只基金位居麦澜德十大流通股东。华夏稳增混合（519029）三季度减持55.05 万股，持有股数70.15万股，占流通股的比例为1.9%。根据测算，今日浮盈赚取约156.44万元。 华夏稳增混合（519029）基金经理为彭海伟。 截至发稿，彭海伟 ...

Group 1 - The core viewpoint of the news is that 麦澜德 experienced a decline in stock price and has significant financing activities, indicating a high level of market interest and potential volatility [1] - As of January 26, 麦澜德's stock price fell by 3.09%, with a trading volume of 95.12 million yuan, and a net financing purchase of 1.08 million yuan [1] - The total financing and securities balance for 麦澜德 reached 125 million yuan, with a financing balance of 124 million yuan, accounting for 7.41% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of September 30, 麦澜德 had 6,402 shareholders, an increase of 17.23%, while the average circulating shares per person decreased by 14.70% [2] - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, a year-on-year increase of 4.01%, while the net profit attributable to shareholders was approximately 96 million yuan, a slight decrease of 0.07% [2] - 麦澜德 has distributed a total of 297 million yuan in dividends since its A-share listing, with 247 million yuan distributed over the past three years [3] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of 麦澜德, 华夏稳增混合 (519029) ranked fourth with 701,500 shares, a decrease of 550,500 shares from the previous period [3] - Notably, 中信建投轮换混合A (003822), 中信建投甄选混合A (008347), and 汇添富成长焦点混合 (519068) have exited the list of top ten circulating shareholders [3]

Group 1 - The core point of the news is that 麦澜德 experienced a decline of 5.05% in its stock price, reaching 49.09 yuan per share, with a trading volume of 168 million yuan and a turnover rate of 9.12%, resulting in a total market capitalization of 4.909 billion yuan [1] - 麦澜德 is a company based in Nanjing, Jiangsu Province, established on January 16, 2013, and listed on August 11, 2022. The company specializes in the research, development, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The main revenue composition of 麦澜德 includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Group 2 - 金元顺安基金 has a significant holding in 麦澜德, with its 金元顺安成长动力灵活配置混合 fund holding 20,000 shares, accounting for 2.88% of the fund's net value, making it the fifth-largest holding [2] - The fund has a total scale of 28.1676 million yuan, with a year-to-date return of 6.62%, ranking 2154 out of 8840 in its category, and a one-year return of 34.98%, ranking 3623 out of 8094 [2] - The fund manager, 孔祥鹏, has been in position for 8 years and 204 days, with a total asset scale of 143 million yuan, while the other manager, 韩辰尧, has been in position for 2 years and 322 days, managing 873 million yuan [3]

Group 1 - The core viewpoint of the news is that 麦澜德 experienced a decline in stock price and had significant financing activities, indicating a high level of market activity and investor interest despite the drop [1] - As of December 4, 麦澜德's stock price fell by 1.25%, with a trading volume of 22.1014 million yuan. The financing buy amount was 2.9007 million yuan, while the financing repayment was 4.7555 million yuan, resulting in a net financing buy of -1.8548 million yuan [1] - The total financing and margin trading balance for 麦澜德 reached 112 million yuan, which accounts for 8.75% of its circulating market value, indicating a high level of financing activity compared to the past year [1] Group 2 - As of September 30, 麦澜德 had 6,402 shareholders, an increase of 17.23% from the previous period, while the average circulating shares per person decreased by 14.70% to 5,752 shares [2] - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, representing a year-on-year growth of 4.01%, while the net profit attributable to shareholders was 95.9987 million yuan, showing a slight decrease of 0.07% year-on-year [2] - 麦澜德 has distributed a total of 297 million yuan in dividends since its A-share listing, with 247 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that 麦澜德 (Milan Medical Technology Co., Ltd.) has seen a stock price increase of 5.04%, reaching 37.52 CNY per share, with a total market capitalization of 3.752 billion CNY as of the report date [1] - The company, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The revenue composition of the company includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Group 2 - Among the top circulating shareholders of 麦澜德, 华夏稳增混合 (Huaxia Stable Growth Mixed Fund) reduced its holdings by 550,500 shares in the third quarter, now holding 701,500 shares, which accounts for 1.9% of the circulating shares [2] - The fund has achieved a year-to-date return of 36.83% and a one-year return of 32.03%, ranking 1759 out of 8199 and 2264 out of 8131 in its category, respectively [2] - The fund manager, 彭海伟 (Peng Haiwei), has a tenure of 11 years and 322 days, with the fund's total asset size at 1.314 billion CNY [3]

Core Viewpoint - 麦澜德's stock price has shown significant volatility, with a year-to-date increase of 73.20%, but a recent decline of 4.53% over the past five trading days, indicating potential market fluctuations and investor sentiment changes [1][2]. Company Overview - 南京麦澜德医疗科技股份有限公司, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services related to pelvic and postpartum rehabilitation products [1]. - The company's revenue composition includes: pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1]. Financial Performance - For the period from January to September 2025, 麦澜德 reported a revenue of 344 million yuan, reflecting a year-on-year growth of 4.01%, while the net profit attributable to shareholders was approximately 95.6 million yuan, showing a slight decrease of 0.07% [2]. - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [3]. Shareholder and Market Activity - As of September 30, 2025, 麦澜德 had 6,402 shareholders, an increase of 17.23% from the previous period, with an average of 5,752 circulating shares per shareholder, down by 14.70% [2]. - The stock has seen significant trading activity, with a recent net inflow of 686,900 yuan from major funds, indicating ongoing interest from institutional investors [1].

Group 1 - The core point of the article highlights the recent decline in the stock price of Mylande, which fell by 5.02% to 41.63 CNY per share, with a trading volume of 63.59 million CNY and a turnover rate of 4.08%, resulting in a total market capitalization of 4.163 billion CNY [1] - Mylande Medical Technology Co., Ltd. specializes in the research, development, production, sales, and services related to pelvic floor and postpartum rehabilitation products, with its main business revenue composition being 36.98% from pelvic rehabilitation products, 33.10% from reproductive rehabilitation products, 24.32% from consumables and accessories, 2.77% from sports rehabilitation products, and 2.18% from other supplementary products [1] Group 2 - Among Mylande's top ten circulating shareholders, a fund under Huatai PineBridge holds a position, having reduced its holdings by 29.94 thousand shares in the second quarter, now holding 36.38 thousand shares, which accounts for 0.99% of the circulating shares [2] - The Huatai Growth Focus Mixed Fund (519068) has a total asset size of 2.851 billion CNY and has achieved a year-to-date return of 18.61%, ranking 4578 out of 8160 in its category, with a one-year return of 15.36%, ranking 5161 out of 8021 [2]

Group 1 - The core viewpoint of the news is that 麦澜德 (Milan Medical Technology Co., Ltd.) has seen a 5% increase in stock price, reaching 42.00 CNY per share, with a total market capitalization of 4.2 billion CNY [1] - The company, established on January 16, 2013, and listed on August 11, 2022, specializes in the research, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The main revenue composition of the company includes pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Group 2 - From the perspective of major circulating shareholders, 汇添富成长焦点混合 (Huitianfu Growth Focus Mixed Fund) reduced its holdings by 29.94 thousand shares, now holding 36.38 thousand shares, which accounts for 0.99% of the circulating shares [2] - The fund has achieved a year-to-date return of 15.32%, ranking 4855 out of 8161 in its category, and a one-year return of 8.62%, ranking 5748 out of 8015 [2] - The fund manager, 陈潇扬 (Chen Xiaoyang), has been in position for 3 years and 290 days, with the fund's total asset size at 2.851 billion CNY [3]

Core Insights - 麦澜德 experienced a decline of 2.20% in stock price on October 13, with a trading volume of 59.89 million yuan [1] - The company reported a financing net buy of -7.29 million yuan on the same day, indicating more financing repayments than new purchases [1] - As of October 13, the total financing and securities lending balance for 麦澜德 was 126 million yuan, which is 8.53% of its market capitalization [1] Financial Performance - For the first half of 2025, 麦澜德 achieved operating revenue of 241 million yuan, reflecting a year-on-year growth of 5.62% [2] - The net profit attributable to shareholders for the same period was 63.92 million yuan, showing a year-on-year decrease of 11.96% [2] Shareholder Information - As of June 30, 2025, 麦澜德 had 5,461 shareholders, an increase of 10.84% from the previous period [2] - The average number of circulating shares per shareholder was 6,743, which decreased by 9.78% compared to the last period [2] - The company has distributed a total of 268 million yuan in dividends since its A-share listing [3] Institutional Holdings - Among the top ten circulating shareholders, 华夏稳增混合 (519029) is the third largest, holding 1.25 million shares, an increase of 141,700 shares from the previous period [3] - 中信建投轮换混合A (003822) and 中信建投甄选混合A (008347) are new entrants in the top ten shareholders, holding 656,200 shares and 563,300 shares respectively [3] - 汇添富成长焦点混合 (519068) is the tenth largest shareholder, holding 363,800 shares, a decrease of 299,400 shares from the previous period [3]

Core Insights - On October 10, 麦澜德 experienced a decline of 1.78% with a trading volume of 61.79 million yuan [1] - The company reported a financing buy-in of 9.14 million yuan and a financing repayment of 10.99 million yuan, resulting in a net financing buy of -1.86 million yuan [1] - As of October 10, the total financing and securities balance for 麦澜德 was 133 million yuan, which accounts for 8.83% of its circulating market value, indicating a high level of financing [1] Financing and Securities - 麦澜德's financing buy on October 10 was 9.14 million yuan, with a current financing balance of 133 million yuan, exceeding the 80th percentile of the past year [1] - There were no shares sold or repaid in the securities lending market on the same day, with a securities lending balance of 0.00 yuan, also indicating a high level [1] Company Overview - 南京麦澜德医疗科技股份有限公司, established on January 16, 2013, and listed on August 11, 2022, focuses on the development, production, sales, and services related to pelvic floor and postpartum rehabilitation products [1] - The company's main revenue sources include pelvic rehabilitation products (36.98%), reproductive rehabilitation products (33.10%), consumables and accessories (24.32%), sports rehabilitation products (2.77%), and other products (2.84%) [1] Financial Performance - As of June 30, 麦澜德 had 5,461 shareholders, an increase of 10.84% from the previous period, with an average of 6,743 circulating shares per person, a decrease of 9.78% [2] - For the first half of 2025, 麦澜德 reported a revenue of 241 million yuan, a year-on-year increase of 5.62%, while the net profit attributable to shareholders was 63.92 million yuan, a decrease of 11.96% [2] Dividend and Shareholding - Since its A-share listing, 麦澜德 has distributed a total of 268 million yuan in dividends [3] - As of June 30, 2025, major shareholders include 华夏稳增混合 (519029) as the third-largest shareholder with 1.25 million shares, and 中信建投轮换混合A (003822) as a new fifth-largest shareholder with 656,200 shares [3]